Leonard Freedman, President of the Global Biological Standards Institute in Washington, D.C. published a paper last year in PLOS Biology which it was calculated that $28 billion is wasted yearly on irreproducible pre-clinical research in the US. In our interview with Dr. Freedman, posted on LinkedIn, he says that while that number became a big focus in the press, that this paper also outlined very achievable fixes for some of the most pervasive problems behind the In Vitro Reproducibility Crisis.
In Part Two, Dr. Henn talked with Dr. Ian Mudway about difficulties in getting publishers and the greater scientific community to embrace his important findings. Here, they discuss overcoming scientific inertia and paradigm shift. Learn more about lowering the barriers to publish scientific findings in our interview with Dr. Ian Mudway today.
In Part One, Dr. Henn talked with Dr. Ian Mudway about his recent publication , “Quantifying the magnitude of the oxygen artefact inherent in culturing airway cells under atmospheric oxygen versus physiological levels.”
Here, they discuss barriers to change in the scientific community.
Ian Mudway is a Lecturer in Respiratory Toxicology at King’s College in London. He has been active in air pollution research, participating in Air Quality conferences, speaking out on BBC World News and in the Guardian newspaper, and advising the World Health Organization.
Here, Dr. Henn talks with Dr. Mudway about his recent publication , “Quantifying the magnitude of the oxygen artefact inherent in culturing airway cells under atmospheric oxygen versus physiological levels.” In the part one of our interview with Dr. Ian Mudway, we discuss the effect of oxygen conditions in research for airway cells.
At what oxygen level should I culture my umbilical cord-derived hematopoietic stem cells? It’s not a question you will hear on Jeopardy, but it is a critically important question for research involving cord blood stem cells.
Hematopoietic stem cells from umbilical cord blood (CB-HSC) have been shown to be beneficial for treating leukemia1,2, neuroblastoma3, and is of great interest for other disease applications. NIH-funded clinical trials listed on clinicaltrials.gov include studies of CB-HSC for immunodeficiencies, autoimmune diseases, sickle cell, cerebral palsy, complications of prematurity, and stroke. However, individual cord blood units often do not have the cell yield needed for a full transplant, requiring the pairing of HLA- partially matched cord blood units for a single transplant4. This presents obvious drawbacks in limiting the numbers of patients that can be treated.